Targeted DNA sequencing and in situ mutation analysis using mobile phone microscopy

Abstract

Molecular diagnostics is typically outsourced to well-equipped centralized laboratories, often far from the patient. We developed molecular assays and portable optical imaging designs that permit on-site diagnostics with a cost-effective mobile-phone-based multimodal microscope. We demonstrate that targeted next-generation DNA sequencing reactions and in situ point mutation detection assays in preserved tumour samples can be imaged and analysed using mobile phone microscopy, achieving a new milestone for tele-medicine technologies.

ARTICLE

Received 21 Jul 2016 | Accepted 11 Nov 2016 | Published 17 Jan 2017

DOI: 10.1038/ncomms13913 OPEN

Targeted DNA sequencing and in situ mutation analysis using mobile phone microscopy

Malte Khnemund1,2,*, Qingshan Wei3,4,5,*, Evangelia Darai2, Yingjie Wang3, Ivn Hernndez-Neuta2, Zhao Yang3, Derek Tseng3, Annika Ahlford2,6, Lucy Mathot1, Tobias Sjblom1, Aydogan Ozcan3,4,5 & Mats Nilsson1,2

Molecular diagnostics is typically outsourced to well-equipped centralized laboratories, often far from the patient. We developed molecular assays and portable optical imaging designs that permit on-site diagnostics with a cost-effective mobile-phone-based multimodal microscope. We demonstrate that targeted next-generation DNA sequencing reactions and in situ point mutation detection assays in preserved tumour samples can be imaged and analysed using mobile phone microscopy, achieving a new milestone for tele-medicine technologies.

1 Science for Life Laboratory, Department of Immunology, genetics and pathology, Uppsala University, Box 815, 751 08 Uppsala, Sweden. 2 Science for Life Laboratory, Department of Biophysics and biochemistry, Stockholm University, Sweden, Box 1031, Se-171 21 Solna, Sweden. 3 Electrical Engineering Department, University of California, Los Angeles, Los Angeles, California 90095, USA. 4 Bioengineering Department, University of California, Los Angeles, Los Angeles, California 90095, USA. 5 California NanoSystems Institute (CNSI), University of California, Los Angeles, Los Angeles, California 90095, USA.

6 Devyser AB, Instrumentvagen 19, 126 53 Stockholm, Sweden. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to A.O. (email: mailto:[email protected]

Web End [email protected] ) or to M.N. (email: mailto:[email protected]

Web End [email protected] ).

NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications 1

ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13913

Molecular diagnostics at the point of care (POC) is currently by and large an unmet need in resource-limited settings. Efcient management of a wide

range of disease conditions is severely limited by the lack of molecular information. Here we focus our attention to the emerging eld of molecular pathology, in which molecular analysis increasingly complements traditional morphology-based diagnosis of cancer for improved treatment precision1,2. Due to assay complexity and infrastructure requirements, such diagnostic assays are usually outsourced to specialized labs and sequencing centres. A parallel development is digital pathology, which enables pathologists to view samples and analyse molecular diagnostic data remotely, hence making the best use of the limited resource of professional pathology expertise. Mobile phones may further accelerate this emerging trend of tele-medicine and enable on-site implementation of digital pathology in resource-limited settings by supplying a cost-effective technology infrastructure for imaging and diagnostic analysis3. With their rapidly expanding imaging and sensing capabilities, computational power, and connectivity, mobile phones help translating biomedical measurements from lab environments to the POC and eld settings39. For example, using the CMOS imager chips of mobile phone cameras, it is now possible to image tumour samples over large elds of view, with spatial resolution and image quality matching high-end pathology microscopes3.

Here we demonstrate a new milestone for mobile-phone-based biomolecular analysis and diagnostics that may facilitate transferring molecular diagnostic data from the POC to the point-of-expertise, providing a cost-effective means for molecular diagnostics even in resource-limited settings. We show that a cost-effective and compact multimodal microscope integrated on a mobile phone can be used for (i) targeted DNA sequencing and (ii) in situ point mutation analysis that allow integrating molecular analysis with tumour tissue morphology.

ResultsQuantication of RCA products with mobile phone microscopy. First, we aimed to image individual rolling circle amplication (RCA)-amplied single molecules, generated on glass slides and inside preserved cells and tissues using a mobile-phone-based microscope. For these goals, we designed and 3D-printed a light-weight optomechanical attachment that is integrated with the existing camera module of a mobile phone (Fig. 1ad). This optical attachment contains two compact laser diodes (at 532 and 638 nm) for multicolour uorescence imaging (Fig. 1a) and a white light-emitting diode (LED) for bright-eld transmission imaging (Fig. 1b,d). An integrated sample holder, consisting of a z-movement stage (Supplementary Fig. 1a, red part) and an xy-movement stage (Supplementary Fig. 1a, blue part), enables three dimensional movement and alignment of the inserted sample slide. This optomechanical attachment to the mobile phone is also equipped with a cost-effective external lens module (focal length: 2.6 mm) providing a half-pitch resolution of 0.98 mm and an imaging eld of view of B0.8 mm2 (Fig. 1; Supplementary Fig. 1b). For the molecular analysis, we developed targeted sequencing library preparation schemes based on selector probes (refs 10,11) (Fig. 1e; Supplementary Note 1) and padlock probes in situ (refs 12,13) (Fig. 1g), and RCA to generate micron-sized DNA coils that consist of hundreds of concatemerized repeats of the circular template and that can each be brightly labelled with uorescent hybridization probes14 or sequenced15. We then established that individual RCA products (RCPs) can be discriminated and precisely quantied by our mobile-phone-based microscope over a 4-log

dynamic range (1 fM10 pM), demonstrating its utility to image and analyse individual RCA-amplied single molecules (Fig. 2a,b, Supplementary Software 1a).

Targeted DNA sequencing for point mutation analysis. RCPs can be used as sequencing libraries in next-generation sequencing (NGS) applications15. To investigate whether our mobile-phone- based microscope can be used to read NGS reactions, we imaged and quantied sequencing by ligation (SBL) reactions of RCPs generated on standard microscopy slides (Fig. 2ce, Supplementary Note 1, Supplementary Software 1b). To conrm that SBL reactions are base-specic, we generated sequencing libraries from synthetic KRAS fragments with either wild-type sequence, resulting in base G-specic Cy3 stain (Fig. 2c, Supplementary Fig. 2a), or with a codon 12 mutation, generating a base A-specic Cy5 stain (Fig. 2d, Supplementary Fig. 2b). To test the feasibility of detecting small amounts of mutant KRAS DNA within the background of wild-type DNA, synthetic fragments were sequenced in a ratio of 1:1,000 mutant:wild type (Fig. 2e). Our imaging results show that nine mutant RCPs with base A-specic stain (Cy5 labelled) were successfully detected using the mobile phone microscope among 1,552 wild-type RCPs with G-specic sequencing signal (Cy3 labelled) (Fig. 2e, inset). At such high sequencing depths (41,000-fold per eld of view on our mobile microscope), a high mutation detection sensitivity (o1%) can potentially be achieved that is comparable to FDA-approved PCR-based KRAS diagnostic tests (the therascreen KRAS RGQ PCR Kit, https://www.qiagen.com/us/resources/technologies/oncology-companion-diagnostics/therascreen-kras-test-usa-labs/#performance

Web End =https://www.qiagen. https://www.qiagen.com/us/resources/technologies/oncology-companion-diagnostics/therascreen-kras-test-usa-labs/#performance

Web End =com/us/resources/technologies/oncology-companion-diagnostics/ https://www.qiagen.com/us/resources/technologies/oncology-companion-diagnostics/therascreen-kras-test-usa-labs/#performance

Web End =therascreen-kras-test-usa-labs/#performance ).

Next, we validated the targeted sample preparation and sequencing scheme (Fig. 1e) on genomic DNA extracted from cell lines. Sequencing the second base of codon 12 in genomic DNA extracted from A427 cells (heterozygous for a codon 12 mutation) with our mobile phone microscope resulted in 52% Cy3- and 48% Cy5-stained RCPs, well representing the expected ratio of mutant and wild-type molecules (Fig. 2f,g). Mobile sequencing of genomic DNA from Onco-DG1 cells (homozygous KRAS wild type) resulted in predominantly wild-type-specic sequencing signals (Fig. 2g). Regular benchtop uorescence microscopy, combined with a custom-developed sequencing analysis pipeline16 (Supplementary Software 1c), generated sequencing results (Supplementary Fig. 3) that are very well consistent with our mobile-phone-based measurements, demonstrating the utility of our mobile targeted DNA sequencing approach. We further sequenced the extracted DNA from three different colon cancer biopsies. All three tumour samples were measured KRAS wild type through our mobile-phone-based targeted sequencing (Fig. 2g), also conrmed by both regular microscopy-based sequencing analysis (Supplementary Fig. 4) and diagnostic PCR analysis (Supplementary Fig. 5).

Single cell in situ analysis can nd rare KRAS mutant cells. An alternative mutation analysis scheme, without the need for DNA extraction and sequencing, is genotyping directly in situ within tumour tissue sections. Padlock probes, combined with RCA, enable in situ analysis of point mutations directly in preserved cells and tissues, adding molecular information to tissue morphology13,17. These in situ generated RCPs can be imaged and quantied using the presented mobile-phone-based multimodal microscopy platform (Figs 1h and 3). We also performed an in situ padlock probe-based single base discrimination assay (Fig. 1g) to target the most prevalent mutations in KRAS codon 12 and 13 (ref. 17) occurring in 3040% of human colon cancers1,2. The multiplex padlock probe

2 NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13913 ARTICLE

a b c d

532 nm laser

White LED

Lens

3D stage

638 nm laser

Filter

e f g h

GenomicDNA Restriction

digestion

cDNA

Mutant

Ligation

1

0

KRASDNA fragment

KRAS selector probe

Anchor primer

Codon 12+13

Wild type

KRAS RNA

RCA

A Cy5 G Cy3

Mutant label

Wild-type label

Figure 1 | Multimodal mobile microscopy device and schematics of RCA assays. (a,b) 3D schematic illustration of the inner structure and the optical design of the mobile-phone-based microscopy platform. (c,d) Photographs of the mobile-phone-based microscope from different viewing perspectives. Mobile phone screen of (d) shows a bright-eld image of xated A549 cells captured by the phone. (e) DNA sequencing sample preparation scheme: genomic DNA is restriction digested and the KRAS DNA fragment selectively circularized on KRAS selector probes attached to slides. The DNA fragments are ligated and amplied on the slide, and the RCA products sequenced by unchained SBL chemistry15,20. DNA sequencing reactions are then imaged through our mobile phone microscope. (f) Dual-colour mobile phone microscope image of a targeted SBL reaction of KRAS codon 12 in genomic DNA extracted from A427 cells which are heterogeneous for a KRAS codon 12 mutation. RCPs are either stained with Cy3 corresponding to base G (KRAS wild type), or Cy5 corresponding to base A (KRAS mutant). Scale bar, 50 mm. (g) Schematic diagram of in situ point mutation detection assay through padlock probes and RCA. KRAS mRNA is converted to cDNA, which is targeted by single-base-discriminating padlock probes. Mutant specic padlock probes are ligated and amplied through RCA. Wild-type-specic probes do not ligate on mutated KRAS cDNA and generate no RCP. (h) A full eld of view image of the A549 cell line with in situ RCA detected codon 12 point mutations, imaged with our mobile phone uorescence microscope. Scale bar, 200 mm (full eld of view); Scale bar, 20 mm (inset).

panel was rst validated on cell lines for high mutantwild type discrimination of the most recurrent KRAS codon 12 and 13 alleles (Supplementary Fig. 6). In situ RCA conditions were then optimized for mobile phone microscopy-based imaging with an optimal RCP intensity after a reaction time of 120 min (Supplementary Fig. 7). To quantify RCPs using our mobile phone microscope, we also developed a machine-learning-based image analysis algorithm that permits automated RCP recognition and digital counting (see Methods, and Supplementary Software 2). In total, 14 recognition features (including for example, mean, maximum and minimum intensities) were extracted from individual RCPs in the training set, which included 1,136 RCPs in total. Using this machine learning and training process, an average detection accuracy of 94.94.5% was achieved using our mobile phone microscope images, compared to 96.91.8% using the images obtained through a regular benchtop microscope.

Next, we tested the utility of this mobile microscope combined with the in situ genotyping assay to detect rare cancer cells within a high background of normal cells through a cell spike-in experiment. Cells from the A549 cell line, carrying a mutation in KRAS codon 12, were spiked into a background of KRAS wild type Onco-DG1 cells in ratios of 1:100 and 1:1,000 (Fig. 3a,b and Supplementary Fig. 8). After the in situ padlock assay, the cells were imaged with the mobile phone microscope and the acquired images were processed as described above. KRAS mutant cells were detected in low ratios of 1:1,000, yielding a

mutant:wild type RCP ratio of 0.49%, compared to 0.15% measured in KRAS wild-type cells only (Supplementary Fig. 8b). These data match well with the results obtained using a conventional benchtop microscope (Supplementary Fig. 8b), demonstrating the utility of our mobile platform to identify cancer cells with oncogene mutations among the majority of wild-type cells.

Tissue in situ analysis accurately scores tumour samples. Finally, we tested the clinical applicability of our approach for detecting KRAS mutations directly in colon tumour tissue sections (Fig. 3c,d). Our mobile-phone-based multimodal microscope delivers dual-colour uorescence images that very well match with conventional microscope images of the same samples as illustrated in Supplementary Fig. 9. We imaged several randomly chosen areas on 6 different colon cancer tumour samples (Supplementary Fig. 10) and quantied RCPs (Supplementary Software 3), based on which the genotype is determined (Table 1). Our results revealed that mobile phone microscope-based in situ genotyping resulted in 100% concordance to clinical NGS analysis (Table 1) and whole tissue scanning with an automated benchtop uorescence microscope (Supplementary Table 1). Using mobile-phone-based in situ genotyping, a minimum of six images of randomly chosen areas were required to detect a sufcient number of mutant RCPs (Supplementary Fig. 11; Supplementary Note 2) and score

NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications 3

ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13913

all the mutant samples in concordance with clinical NGS data and whole tissue scanning (Table 1; Supplementary Table 1). These results provide evidence that our mobile phone multimodal microscopy platform can be used to analyse RCA-based in situ genotyping assays and accurately genotype cancer patient biopsies directly in situ, which may facilitate integrating molecular diagnostics with tumour morphology directly in pathologists ofces and POC.

DiscussionThe sample processing steps in our approach are relatively simple to perform and do not require advanced equipment or infrastructure. Yet, in manual operation, preparation of reaction mixes and pipetting steps require a lab technician. The bottleneck in molecular pathology, however, is usually not the availability of lab technicians, but of pathologists. Nevertheless, further automation may facilitate broader implementation and use of our approach in clinical settings. To explore the initial feasibility of integration with micro-uidics, we also imaged in situ RCA assays using the mobile phone microscope directly through a ow cell attached to a sample slide (Supplementary Fig. 12), which showed quite promising results, suggesting that liquid handling can also be integrated onto the same mobile-phone-based interface. However, preparation of tumour cryo-sections, as used in our work, still requires skilled personnel and infrastructure, which may not be available in resource-limited settings. As an alternative, tumour touch imprints can be used as a simple method to prepare samples at POC, especially in resource-limited environments18. In this rapid procedure, tumours are gently pressed onto a microscope glass slide leaving a layer of cells attached to the surface with partially preserved morphological structure18. These tissue fragments can then be subjected to the point mutation assay17 and quantied using our mobile platform.

The sensitivity of our mobile-phone-based targeted sequencing method for extracted tumour DNA is currently limited by the sequencing depth and accuracy to B5% mutant:wild-type ratio, which is similar to diagnostic KRAS PCR Kits (the therascreen KRAS RGQ PCR Kit, https://www.qiagen.com/us/resources/technologies/oncology-companion-diagnostics/therascreen-kras-test-usa-labs/#performance

Web End =https://www.qiagen.com/ https://www.qiagen.com/us/resources/technologies/oncology-companion-diagnostics/therascreen-kras-test-usa-labs/#performance

Web End =us/resources/technologies/oncology-companion-diagnostics/ther https://www.qiagen.com/us/resources/technologies/oncology-companion-diagnostics/therascreen-kras-test-usa-labs/#performance

Web End =ascreen-kras-test-usa-labs/#performance ). Our sequencing depth (currently 100200 ) can be increased by using higher DNA

concentrations. Higher accuracy can be achieved by adding a third uorescent channel on our mobile microscope and perform a common RCP anchor stain, which aids in discarding auto-uorescent objects (Supplementary Figs 3 and 4) that currently contribute to nonspecic signals and limit the accuracy. Ultimately, sequencing several bases will increase our accuracy by discarding auto-uorescent objects that do not change colour over sequencing cycles.

In conclusion, mobile-phone-enabled molecular diagnostic analysis may provide a simple, cost-effective and yet powerful means to integrate molecular marker information with traditional morphology analysis and might further help digital molecular pathology become widely accessible at POC ofces and even in resource-limited settings. The impact of this approach goes beyond molecular pathology. Other important applications may include for example, infectious disease diagnostics, where pathogen identity and load, as well as antibiotic resistance markers, can potentially be measured using the same mobile platform. With a simple DNA sequencing library preparation scheme and the capability to image NGS reactions, mobile-phone-enabled imaging and sensing tools may soon be used for targeted DNA sequencing in clinical settings and POC ofces, with the potential to dramatically decrease the cost of NGS-based diagnostics globally.

a b

R2 = 0.992

10 pM

1 pM

Number of RCPs

104

103

102

101

100

14

15 13 12 11

100 fM Concentration

Mobile wt: 10 pM mt: 10 fM

10 fM

c

e

1

0

1

0

wt

d

No. of RCPs

10 10 10 10 10

mt

f g

A G

Relative frequency

1.0

0.5

0.0

i

ii

A427

OncoDG1

Tumour 1

Tumour 2

Tumour 3

Figure 2 | Mobile phone microscopy-based targeted DNA sequencing. (a) Amplied single-molecule detection through RCA and mobile phone microscopy: selected regions within images of 10 pM to 10 fM RCPs are depicted. Scale bar, 50 mm. (b) Quantication of RCPs generated from a log10 dilution series of synthetic circular templates. Error bars: 1 s.d. from the mean, n 3; linear regression is plotted as straight line. (c) KRAS wild

type and (d) KRAS mutant (codon 12 mutation) synthetic DNA fragments were circularized through selector probes, amplied through RCA, and the rst base in codon 12 sequenced by unchained SBL chemistry. Sequencing reactions were imaged at both of the uorescent channels using the mobile phone microscope and these channels were digitally superimposed. Scale bar, 20 mm. (e) Synthetic KRAS fragments at a ratio of 1:1,000 mutant/wild type were sequenced and the reaction imaged through mobile phone microscopy. Cy3 stained RCPs (wild typebase G, green bar) and Cy5 stained RCPs (mutantbase A, red bar) were quantied and plotted in the inset graph. Red arrows in the mobile phone image point to RCPs that show a Cy5 sequencing signal. Scale bar, 200 mm. (f) Mobile phone microscopy-based sequence analysis: (i) uorescence imaging of sequencing reaction, and (ii) base calling through a custom-written automated image analysis algorithm. Scale bar, 50 mm. (g) Quantication of sequencing experiments of extracted genomic DNA from cell lines and colon tumour biopsies using our mobile phone microscope. Relative frequencies of mutant (red bars) and wild type (green bars) RCPs are plotted.

4 NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13913 ARTICLE

a b c d

Cy5 (wt) Cy3 (mt) Trans

Cy5 (wt) Cy3 (mt)

A549/Onco-DG1 1:100

Figure 3 | In situ KRAS mutation detection in tumour tissues. (a,b) Cell spike-in imaging experiments: A549 cells carrying a KRAS codon 12 mutation were spiked into Onco-DG1 (wild type) cells at a ratio of 1:100. Wild-type RCPs, labelled with Cy5, and mutant RCPs, labelled with Cy3, were imaged using our mobile phone microscope. (a) Mobile phone microscope image with Cy5 and Cy3 channels digitally superimposed. (b) Mobile phone bright-eld image, digitally superimposed with Cy5 and Cy3 channels, visualizes cell boundaries, enabling specic assignments of RCPs to individual cells and identication of KRAS mutant cells among wild-type cells. Inset: zoomed-in region from b shows rare KRAS mutant cells within the majority of wild-type cells. (c,d) In situ KRAS mutation detection in colon cancer tumour sections. (c) Mobile-phone-based uorescence image of a KRAS wild-type tumour section (sample E) and (d) a KRAS mutant tumour section (sample A), digitally superimposed with base-calling results. Inset pie charts show the ratio between wild type (red) and mutant (green) RCPs in corresponding images. Scale bar, 100 mm (ad); 10 mm (b, inset).

Table 1 | Mobile-phone-based in situ KRAS mutation analysis of colon tumour samples.

Tumour sample No. of ROIs No. of MT RCPs No. of WT RCPs Ratio MT/WT Score Clinical NGS A 14 82 345 23.8% Mutant G-12S 18%

E 9 3 546 0.6% Wild type Wild typeF 7 50 262 19.1% Mutant G-12V 37%

I 8 140 255 54.9% Mutant G-12V (ratio NA) E1 6 51 706 7.2% Wild type Wild typeJ 6 64 857 7.5% Wild type Wild type

MT, mutant; RCPs, rolling circle amplication products; ROIs, region of interests; NA, not applicable; NGS, next-generation sequencing; WT, wild type.

Six different colon cancer tumour samples were subjected to in situ KRAS mutation detection assay and several randomly chosen ROIs within the samples were imaged with our mobile phone microscope. KRAS mutant and KRAS wild-type RCPs were quantied and the corresponding measured ratios and genotyping scores are listed together with the results of NGS-based clinical analysis per tumour sample.

Methods

Ethical permission on human samples. The in situ somatic mutation analyses of cancer and patient-matched normal tissues were approved by the Regional Ethical Review Board of Uppsala (2007/116). The tumour biopsy material used for targeted sequencing analysis and basic clinicopathological data were anonymously provided by pathologists without any patient identity or related information, and do not require ethical permission, since only research with biological material that can be traced to a person is subject to ethical approval (The Swedish ethical review act; 2003:460, section 4;3).

Design of the multimodal cellphone-based microscope. A handheld cellphone-based multimodal microscope was developed by integrating two battery-powered laser diodes (532 nm at 75 mW, Z-Bolt, and 638 nm at 180 mW, Mitsubishi Electric) into a 3D printed optomechanical attachment. Both of these laser diodes were mounted on a focusing stage, each with a tilted incidence angle of B75

creating a strong background rejection suitable for dark-eld imaging and their illumination spots coincided on the sample plane. The uorescence signals of the samples were collected by an external lens (focal length: 2.6 mm, UCTronics) added in front of the cellphone camera module and passed through a dual-band emission lter (577/690 nm, Semrock) before reaching the cellphone CMOS image sensor. Using the same cellphone-based microscope design, bright-eld images of the samples can also be obtained by illuminating the sample slide vertically with a white LED (897-1183-ND, DigiKey) that was mounted above the sample. Allthe light sources were powered by a rechargeable battery pack (3.7 V, 1,700 mAh, Vivitar).

The 3D movable sample stage consisted of two moving parts (that is, redand blue parts as shown in Supplementary Fig. 1a) which were also created by 3D printing. The red piece was connected to the basement of the mobile phone attachment via a miniature dovetail stage (DT12, Thorlabs), and served as the z-stage, moving the sample slide in the z direction for focusing adjustment. The lateral movement of the sample slide (x and y directions) was controlled by the blue

part which was connected to the red piece via a 2-axis dovetail translation stage (DT12XY, Thorlabs).

A Nokia Lumia 1020 mobile phone was used in our prototype. It is equipped with a 1/1.5 inch camera sensor that provides 38 megapixels per image(7,152 5,368, 4:3 mode) with a pixel size of B1.1 mm. The camera also has a

long focal length of 6.86 mm and together with the external lens that we have used in our microscope design, it provides an effective magnication factor of B2.6X.

Mobile-phone-based image acquisition. All the three illumination sources (532 nm laser diode, 638 nm laser diode, and white LED) of the mobile phone microscope can be turned on and off independently. Each laser diode provides an oblique illumination angle (B75) with their illumination spots coinciding on the focal plane of the mobile microscope. Multicolour imaging was achieved by switching one laser diode on at a time, and uorescent signals of the samples were separated from the excitation by using a multi-band uorescence emission lter. For imaging of individual RCPs, a sample slide of interest was inserted into the mobile device from the side. First, the white LED was turned on to align and bring the sample slide into focus using the bright-eld imaging mode. Then, 532and 638 nm laser diodes were turned on sequentially and multiple cellphone uorescence images (NZ5) of the same ROI at each uorescent channel were captured. All the mobile phone images were recorded in a lossless digital negative (DNG) format by using the default smartphone camera application (that is, Nokia Pro Cam) with the same settings (focusing, white balance, ISO and integration time: 4 s per frame).

Digital counting of RCPs using machine learning. A machine-learning-based RCP counting algorithm was developed to process the acquired mobile phone microscope images (Supplementary Software 2). The image processing starts with the conversion of the acquired DNG images into 16-bit single-channel TIFF images (using the green channel for Cy3 staining and the red channel for Cy5 staining, respectively). Next, these cellphone image frames of the same ROIs

NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications 5

ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13913

(NZ5) are averaged for both Cy3 and Cy5 channels in order to improve the signal-to-noise ratio of the uorescent images. The background noise of the averaged images is further reduced by Gaussian ltering. Finally, the Cy3, Cy5, and the transmission/bright-eld images of the mobile phone microscope are co-registered and aligned with respect to each other using common spatial features to create digitally superimposed multimodal images. Our machine learning algorithm utilizes a random forest approach to differentiate real RCP signals from background noise, which combines bagging strategy and the randomness of the features to reduce overtting. The training libraries for machine learning were established by extraction of characteristic image features from individually validated RCPs using a benchtop uorescence microscope (Leica TCS SP5, HCX PL APO CS 40 objective, NA 1.25, oil). A total of 14 different image features

including for example, mean, maximum and minimum intensities of individual RCPs were extracted from 20 Cy3 channel images and 20 Cy5 channel images, respectively, and used as a training set for blind counting and analysis of newly acquired Cy3 and/or Cy5 mobile phone microscope images in future mobile microscopy experiments. The gold standard RCP counts used in our comparison were obtained from benchtop microscope images (for example, Supplementary Fig. 8a) by using an intensity threshold-based automated algorithm. While this automated counting in the current study was done using a desktop computer, for both the benchtop and mobile-phone-based microscope images, it is also possible to conduct the same analysis on the smartphone itself using a custom-written application19.

On-slide RCA. Biotinylated circles were prepared by mixing 500 pM biotinylated ligation template, 100 pM padlock probe (Supplementary Table 2), 0.2 mg ml 1

BSA (NEB), 1 phi29 polymerase reaction buffer (33 mM Tris-acetate (pH 7.9),

10 mM Mg-acetate, 66 mM K-acetate, 0.1% (v/v) Tween 20, 1 mM DTT, Thermo Scientic), 680 nM ATP and 20 mU ml 1 T4 ligase in a nal volume of 25 ml.

The mix was incubated for 15 min at 37 C, followed by inactivation of the enzyme at 65 C for 2 min. Circles were diluted 1:10 from 100 pM to 1 fM in binding buffer (10 mM Tris-HCl pH 8, 10 mM EDTA, 0.05% Tween 20, 1 M NaCl). 50 ml secure seals (Grace Biolabs) were mounted on Neutravidin glass slides (Poly-An). 50 ml circle dilutions in duplicates from 10 pM to 1 fM were added and incubated for3 h at room temperature, followed by two washes with PBS Tween 0.05%

(PBS-T).

Rolling circle amplication was performed on slide by adding RCAreaction mix, containing 0.2 mg ml 1 BSA, 1x phi29 polymerase reaction buffer (33 mM Tris-acetate (pH 7.9), 10 mM Mg-acetate, 66 mM K-acetate, 0.1% Tween-20 (v/v), 125 mM dNTPs (DNA Gdansk) and 500 mU ml 1 phi29 polymerase (Olink Biosciences). The reaction was incubated overnight at room temperature.

After washing twice with PBS-T, RCA products were uorescently labelled by addition of 100 nM Cy3 and 100 nM Cy5-modied detection oligonucleotides (Supplementary Table 2) in hybridization buffer (2 SSC, 20% Formamide) and

incubation for 1 h at room temperature. After three washes with PBS-T the secure seals were detached from the slide, followed by an ethanol series (70% 10, 80% 10, 100% 10). The slides were mounted in SlowFade Gold Antifade (Thermo scientic) mounting medium with a 25 60 mm coverslip (Themo Scientic). For

quantication, three randomly chosen positions per duplicate were imaged with the mobile phone microscope and a regular epiuorescence microscope (Zeiss Axio Imager Z2) using a 20 microscope objective. Finally, images were analysed

through CellProler 2.1.2 (Broad Institute) software with an in-house script for RCP recognition and quantication (Supplementary Software 1a).

Targeted sequencing of KRAS codon 12 and 13. To prepare surfaces for sequencing reactions, Neutravidin modied slides (Polyan, Germany) were functionalized with a dense layer of biotinylated selector probes (Supplementary Table 2) by incubation in 200 ml secure seal chambers (Grace Biolabs) in binding buffer containing 1 mM biotinylated selector probe (Supplementary Table 2),10 mM Tris-HCl pH7.5, 5 mM EDTA, 0.1% Tween-20 and 1 M NaCl for 20 min. The mix was removed and the slide washed with PBS (0.05% Tween-20) twice. The secure seal chamber was removed. An in-house PDMS fabricated mini-well gasket with B2 mm2 area wells was applied on top of the slide and clamped so that the micro-well chambers seal on top of the slide. The mini wells serve as conned reaction chambers for the parallel processing of several samples on one slide, which is optional to increase throughput of analysis.

Sequencing libraries were prepared from genomic DNA isolated from cell lines and from colon cancer tumour biopsies by column-based DNA purication (Mini-preparation Kit, Qiagen, Germany). For that purpose approximately 5 106

cells were centrifuged down and the pellet resolved in lysis buffer. Tumour DNA was extracted from 1020 mg tumour biopsy material. Approximately 100 ng ml 1

DNA concentrations were obtained. 500 ng DNA was subjected to restriction digestion in NEB cutsmart buffer (50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium Acetate), 300 mg ml 1 BSA and 0.25 U ml 1 MseI at 37 C for 1 h. Before application to the selector probe functionalized slides, DNA was heat denaturated at 100 C for 10 min and immediately put on ice. DNA samples were mixed with Ampligase buffer (20 mM Tris-HCl pH 8.3, 250 mM KCl, 100 mM MgCl2, 5 mM NAD, and 0.1% Triton X-100), 0.2 mg ml 1 BSA (NEB) and250 mU ml 1 Ampligase (Epicentre) to a nal volume of 20 ml. The samples were then added onto the selector probe functionalized slides in the mini wells, prepared

as described above. The wells were sealed and the reaction incubated overnight at 45 C. During the ligation reaction the genomic MseI KRAS fragments diffuse to the slide surface, the fragment ends hybridize onto the selector probes and are ligated (Fig. 1e, for illustration). The reaction mixtures were removed and the mini wells were detached. 200 ml secure seal reaction chambers were mounted on top of the area, on which the samples were spotted with help of the mini wells. The continuous steps were then performed in 200 ml chambers to process all the spotted samples in parallel from there on. The spotted samples were washed twice in PBS-Tween 0.05%. The ligated DNA fragments were amplied by RCA through addition of RCA reaction mixture, as described above, with addition of 25 nM KRAS specic compaction oligonucleotide21. The reaction was incubated overnight at room temperature and washed twice with PBS-Tween 0.05%.

Sequencing by ligation reactions were performed by rst hybridizing a common anchor probe to RCA products by addition of 100 nM Alexa750 labelled anchor probe (Supplementary Table 2) in hybridization buffer (2 SSC, 20% Formamide)

and incubation for 1 h at room temperature. After two washes in hybridization buffer without anchor probe and 1 wash in PBS-Tween 0.05%, sequencing reaction mix was applied, containing uorescently labelled 9mer oligonucleotides with degenerated base composition on all positions except for the position that was sequenced (Supplementary Table 2). On the query position nucleotide A was coded by uorescent Cy5 label, T by FITC, G by Cy3 and G by Texas red(or blank). Sequencing reaction mix contained 1 phi29 reaction buffer, 250 nM

ATP (Fermentas), 0.2 mg ml 1 BSA, 100 nM sequencing library each and100 mU ml 1 T4 ligase (DNA GDansk). The reaction was incubated at room temperature (22 C) for 1 h. The reaction was stopped by removing the reaction mix and washing three times in PBS-Tween 0.05%.

To determine the sequenced nucleotide, the reactions were uorescently imaged as described below. To sequence the next nucleotide position, the ligated sequencing library and anchor probe are enzymatically removed through UNG treatment, which removes the Uracils in the anchor probe and weakens the hybridization. For that purpose 20 mU ml 1 UNG (Fermentas) in phi29 reaction buffer and 0.2 mg ml 1 BSA were applied and incubated at room temperature for 10 min. The mixture was removed, the slides washed in PBS-Tween 0.05% twice and then incubated in hybridization buffer (2 SSC, 20% Formamide) for 20 min

at 45 C. The slides were washed twice in PBS-Tween 0.05%. After that the sequencing cycle is repeated by hybridization of the same anchor probe and addition of sequencing reaction mix containing sequencing library probes that interrogate the second nucleotide position.

To image the sequencing reactions the secure seals were detached from the slide, followed by an ethanol series (70% 10, 80% 10, 100% 10). The slides were then mounted in SlowFade Gold mounting medium with coverslip covering the sample area. Mobile-phone-based microscopic imaging was performed as described above. Initially, to validate that sequencing reactions were successful, the reactions were imaged on Zeiss Axio Imager Z2 by uorescent imaging of sequenced RCPs in Alexa 750, Cy3, Cy5, FITC and Texas red channels using a 20 microscope

objective. Alexa750 stain commonly identies all RCPs and helps discarding non-RCPs that are not labelled with Alexa750. Mobile-phone-based microscopic imaging was performed with Cy5 and Cy3 excitation sources as detailed above. Sequencing reactions were quantied in an imaging analysis pipeline with Cell Proler 2.1.2 (Broad Institute), ImageJ and Matlab (Mathworks) software, using a customized version of an analysis pipeline reported previously16 (Pipeline and scripts available in Supplementary Software 1b,c, for mobile images and benchtop images, respectively). Double-stained uorescent signals, with a ratio that is higher than 0.3, were discarded as auto-uorescent objects.

Cell line and tumour section sample preparations. ONCO-DG-1 and A-427 cell lines were cultured in RPMI culture medium (Sigma) without L-Glutamine supplemented with 10% FBS (Sigma) 2 mM L-Glutamine (Sigma) and 1

Penicillin-Streptomycin (PEST, Sigma). A-549 was cultured in DMEM (Sigma) supplemented 10% FBS and 1 PEST. When conuent, all cell lines were seeded

on Superfrost Plus slides (Thermo Scientic) and allowed to attach for 12 h. The cells were then xed in 3% paraformaldehyde (Sigma) in DEPC-treated PBS (DEPC-PBS) for 15 min at room temperature. After xation, slides were washed twice in DEPC-PBS and dehydrated through an ethanol series of 70, 85 and 100% for 4 min each. Secure seal chambers were mounted on the slides, the cells were hydrated by a brief wash with PBS-T (DEPC-PBS with 0.05% Tween 20 (Sigma)) followed by a permeabilization with 0.1 HCl in H2O for 1 min at room temperature. All cell lines were obtained from DSMZ, and were tested negative for mycoplasma infection. According to the International Cell Line Authentication Committee, the Onco-DG1 cell line may be contaminated with OVCAR-3, an ovarian cancer cell line. We used Onco-DG1 in our work, because it has an elevated expression of wild-type KRAS. A potential contamination with OVCAR-3, likewise KRAS wild type, would not have affected our results and conclusions.

Sensitivity and specicity of the KRAS mutation detection assay were validated in cell line dilution experiments. To test for the lowest detectable ratio of mutant cells in a majority of wild-type cells a spike-in experiment was performed. A-549 (KRAS mutant G12S) cells were spiked into Onco-DG1 KRAS wild-type cells in ratio 1:100 and 1:1,000. Cell mixtures were seeded on Superfrost Plus slides and left to attach for 12 h. The slides were washed in cold PBS and xed in 3% PFA for 15 min and further processed as described above.

6 NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13913 ARTICLE

Fresh frozen human tumour tissues from colorectal cancer patients were anonymously obtained from Biobank Uppsala, Sweden, without a link to any patient related information. The somatic mutation analyses of cancer and patient-matched normal tissues were approved by the Regional Ethical Review Board of Uppsala (2007/116). Tape transfer sections (4 mm thick) were xed in 3%

paraformaldehyde in DEPC-PBS for 45 min at room temperature followed by washing with DEPC-PBS. The samples were then treated with 0.01% pepsin (Sigma) in 0.1 M HCl at 37% for 90 s. The digestion was stopped by two washes in DEPC-PBS-T for 2 min. Slides were then dehydrated through an ethanol series of 70, 85 and 100% for 2 min each.

In situ mutation detection assay and tumour genotyping. All in situ reactions were performed in Secure-Seal Chambers (Grace Bio-Labs Inc.), with 50 ml reaction volumes (size 9 mm diameter, 0.8 mm deep) for cells, and either 100 ml (size 13 diameter, 0.8 mm deep) or 200 ml (size 22 mm diameter, 0.8 deep) for tissues, depending on the size of the tissue sample. Reverse transcription reaction mixture was added to the chambers, containing 1 mm cDNA primer (Supplementary Table 2), 20 U ml 1 TranscriptMe reverse transcriptase(DNA Gdansk), 500 mM dNTP (Thermo Scientic), 0.2 mg ml 1 BSA (NEB), and 1 U ml 1 RiboLock RNase Inhibitor (Thermo Scientic) in TranscriptMe reaction buffer (DNA Gdansk). Cell slides were incubated for 3 h and tissue sections overnight at 45 C. After brief wash in PBS-T, cells were postxated in 3% PFA for 10 min and tissues for 30 min at room temperature. The padlock probe assay was performed as follows:17 In brief, 100 nM of each padlock probewas added in a mix of 1 U ml 1 Ampligase (Epicentre), 0.4 U ml 1 RNase H (DNA Gdansk), 1 U ml 1 RiboLock RNase Inhibitor, 50 mM KCl, 20% formamide in Ampligase buffer. Incubation was performed rst at 37 C for 30 min, followed by 45 min at 45 C. After ligation, slides were washed by ushing the chambers with PBS-T. After a brief wash in PBS-T, RCA was performed, in a mix containing 1 U ml 1 phi29 DNA polymerase (Olink Biosciences) in phi29 buffer (Thermo Scientic), 250 mM dNTP, 0.2 mg ml 1 BSA and 5% Glycerol. RCA was performed on cell slides at 37 C for 3 h (30, 60, 120 and 300 min during RCA time course experiment). Tissue samples were incubated overnight atroom temperature. After RCA, the slides were washed with PBS-T. RCPswere visualized by hybridizing 0.5 mM of each corresponding detection probe (Supplementary Table 2) in 2 SSC and 20% formamide (Sigma) for 30 min

at 37 C. Cell nuclei were stained with DAPI during the same step. Secure-seals were removed and the slides were dehydrated through an ethanol series of 70, 85 and 100% for 2 min each. Slides were then mounted using Slowfade Antifade reagent (Life Technologies). Samples were imaged with our mobile phone microscope as described earlier. For comparison, the same samples werealso imaged with Zeiss Axio Imager Z2 using a 20 objective lens with uorescent

channels for DAPI (cell nuclei), Cy3 (mutant specic RCPs), Cy5 (wild-type-specic RCPs), and Alexa750 (Actb specic RCPs).

Mobile-phone-based microscopy images of cell line dilution experiments were analysed and RCPs quantied as described above. For tumour section analysis with mobile phone microscopy, several randomly chosen regions and some predened regions were imaged. tumour sections were additionally scanned in its fullsize using regular benchtop microscopy with an automated scanning stage(Zeiss Axio imager Z2). RCPs in both mobile phone and regular microscope images were analysed using the open source software CellProler (Pipeline available in Supplementary Software 3). RCPs were identied and quantied using different thresholds according to the intensity of the RCPs and the auto-uorescence level of the tissue section. Images were ltered using the Enhance of Suppress Features module and RCPs then identied with the Identify Objects module using size thresholds of 28 pixels and intensity thresholds of 0.10.4, depending on the sample and the level of auto-uorescent structures. Double stained auto-uorescent structures in RCP size and intensity range were identied and ltered out using the Image Math module in CellProler. Finally, wild type and mutant specic RCPs were counted and replotted onto the tumour section image. Ratios of mutant/wild type RCPs per individual ROI and for all the ROIs combined were determined. The threshold for scoring a tumour section as wild type was set at 8%, under which tumour sections were scored as wild type, and above which tumour sections were scored as mutant. The 8% threshold is based on the clinically scored wild-type section that resulted in the highest mutant/wild type ratio (tumour section E1: 7.8% on whole tissue scanning). This background arises from strong auto-uorescent structures, especially in necrotic regions, that can contribute to elevated unspecic mutant RCP counts.

Data availability. Data can be obtained by request from the authors. Image analysis codes and pipelines are available in the Supplementary Software.

References

1. Diaz, L. A. Jr. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537540 (2012).

2. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 15461558

2013:

3. Greenbaum, A. et al. Wide-eld computational imaging of pathology slides using lens-free on-chip microscopy. Sci. Transl. Med. 6, 267ra175 (2014).

4. Ozcan, A. Mobile phones democratize and cultivate next-generation imaging, diagnostics and measurement tools. Lab Chip 14, 31873194

2014:

5. Wei, Q. et al. Fluorescent Imaging of Single Nanoparticles and Viruses on a Smart Phone. ACS Nano 7, 91479155 (2013).

6. Wei, Q. et al. Imaging and sizing of single DNA molecules on a mobile phone. ACS nano 8, 1272512733 (2014).

7. Oncescu, V., Mancuso, M. & Erickson, D. Cholesterol testing on a smartphone. Lab Chip 14, 759763 (2014).

8. Vashist, S. K., Luppa, P. B., Yeo, L. Y., Ozcan, A. & Luong, J. H. Emerging technologies for next-generation point-of-care testing. Trends Biotechnol. 33, 692705 (2015).

9. Laksanasopin, T. et al. A smartphone dongle for diagnosis of infectious diseases at the point of care. Sci. Transl. Med. 7, 273re271 (2015).

10. Dahl, F., Gullberg, M., Stenberg, J., Landegren, U. & Nilsson, M. Multiplex amplication enabled by selective circularization of large sets of genomic DNA fragments. Nucleic Acids Res. 33, e71 (2005).

11. Dahl, F. et al. Multigene amplication and massively parallel sequencing for cancer mutation discovery. Proc. Natl Acad. Sci. USA 104, 93879392 (2007).

12. Nilsson, M. et al. Padlock probes: circularizing oligonucleotides for localized DNA detection. Science 265, 20852088 (1994).

13. Larsson, C., Grundberg, I., Soderberg, O. & Nilsson, M. In situ detection and genotyping of individual mRNA molecules. Nat. Methods 7, 395397

2010:

14. Lizardi, P. M. et al. Mutation detection and single-molecule counting using isothermal rolling-circle amplication. Nat. Genet. 19, 225232 (1998).

15. Drmanac, R. et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 327, 7881 (2010).

16. Ke, R. et al. In situ sequencing for RNA analysis in preserved tissue and cells. Nat. Methods 10, 857860 (2013).

17. Grundberg, I. et al. In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. Oncotarget 4, 24072418 (2013).

18. Dudgeon, L. S. & Patrick, C. V. A new method for the rapid microscopical diagnosis of tumours: with an account of 200 cases so examined. Br. J. Surg. 15, 250261 (1927).

19. Zhu, H. et al. Cost-effective and rapid blood analysis on a cell-phone. Lab Chip 13, 12821288 (2013).

20. Shendure, J. et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309, 17281732 (2005).

21. Clausson, C. M. et al. Compaction of rolling circle amplication products increases signal integrity and signal-to-noise ratio. Sci. Rep. 5, 12317 (2015).

Acknowledgements

We thank Johan Hartman at Karolinska Hospital, Sweden, for biopsy material. We thank Devyser AB for the diagnostic PCR-based analysis of KRAS mutations. Ozcan group acknowledges the support of the United States NSF (Biophotonics, EFRI, BIC Programs), ONR, ARO and HHMI. Nilsson group acknowledges the support of the Swedish Research Council, the Swedish Cancer Foundation (2015/838), SciLifeLab, and the IMI project OncoTrack. Sjblom group acknowledges the support of the Swedish Cancer Foundation (2015/629).

Author contributions

M.K., Q.W., A.A., M.N. and A.O. initiated the project; M.N. and A.O. supervised the project; M.K., Q.W., A.A., E.D. and I.-H.N. planned, conducted experiments and analysed the data; Y.W. and Z.Y. developed the machine-learning algorithms; Q.W. and D.T. designed and fabricated the mobile-phone-based microscope; L.M. and T.S. supplied clinical samples and clinical diagnostic data; T.S. obtained ethical permissions; M.K., Q.W., M.N. and A.O. wrote the manuscript and all the co-authors contributed to the manuscript.

Additional information

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Web End =http://www.nature.com/ http://www.nature.com/naturecommunications

Web End =naturecommunications

Competing nancial interests: A.O. is the co-founder of a company (Cellmic/Holomic LLC) that commercializes mobile diagnostic technologies. The remaining authors declare no competing nancial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Web End =http://npg.nature.com/ http://npg.nature.com/reprintsandpermissions/

Web End =reprintsandpermissions/

How to cite this article: Khnemund, M. et al. Targeted DNA sequencing and in situ mutation analysis using mobile phone microscopy. Nat. Commun. 8, 13913doi: 10.1038/ncomms13913 (2017).

NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications 7

ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13913

Publishers note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the articles Creative Commons license, unless indicated otherwise

in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Web End =http://creativecommons.org/licenses/by/4.0/

r The Author(s) 2017

8 NATURE COMMUNICATIONS | 8:13913 | DOI: 10.1038/ncomms13913 | http://www.nature.com/naturecommunications

Web End =www.nature.com/naturecommunications